Bonus Episode: A podcast exploring the DaBlaCa-13 study, chemoresection with dose-dense mitomycin C (MMC) in patients with recurrent non-muscle-invasive bladder cancer (intermediate-risk)

Tune in for a fascinating discussion with Jørgen Bjerggaard Jensen, Department of Urology, Aarhus University, Denmark, as he explores recent breakthroughs in non-muscle-invasive bladder cancer (NMIBC) management through mitomycin C (MMC) chemoresection.

Jensen addresses the critical need to advance NMIBC management, underscoring its unique status as a disease of field cancerisation. Delving into the study’s main findings, Jensen discusses the efficacy of MMC chemoresection and the potential effectiveness in both low-grade and high-grade Ta tumours. Safety and tolerability aspects are also examined, highlighting the promise this intervention holds for patients and urologists alike.

This content was funded by medac GmbH.